Indication
Deep vein thrombosis prevention
Deep vein thrombosis prevention refers to thromboprophylactic management aimed at inhibiting the development of occlusive thrombi within the deep venous system, most commonly the deep veins of the lower extremities and pelvis. Read more about Deep vein thrombosis prevention
135 drugs 71 manufacturers
Drugs that treat it
Common Deep vein thrombosis prevention therapies.
RIVAROXABAN
RIVAROXABAN
RIVAROXABAN
RIVAROXABAN
RIVAROXABAN
WARFARIN SODIUM
HEPARIN SODIUM IN 0.45% NACL (heparin sodium,porcine in 0.45 % sodium chloride)
HEPARIN SODIUM-0.45% NACL (heparin sodium,porcine in 0.45 % sodium chloride)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonDeep vein thrombosis prevention refers to thromboprophylactic management aimed at inhibiting the development of occlusive thrombi within the deep venous system, most commonly the deep veins of the lower extremities and pelvis.
This clinical indication is targeted toward at-risk populations, including acutely ill medical inpatients, individuals undergoing major orthopedic or general surgery, and patients experiencing prolonged immobility or hypercoagulable states.
Pathophysiologically driven by Virchow's triad—venous stasis, endothelial injury, and hypercoagulability—uninhibited thrombus generation risks clinical manifestations such as limb pain and edema.
Prophylaxis primarily serves to avert severe sequelae, most critically lethal pulmonary embolism and long-term post-thrombotic syndrome.
- nih.gov
Deep vein thrombosis prevention refers to thromboprophylactic management aimed at inhibiting the development of occlusive thrombi within the deep venous system, most commonly the deep veins of the lower extremities and pelvis
- nih.gov
Deep vein thrombosis prevention refers to thromboprophylactic management aimed at inhibiting the development of occlusive thrombi within the deep venous system, most commonly the deep veins of the lower extremities and pelvis This clinical indication is targeted toward at-risk populations, including acutely ill medical inpatients, individuals undergoing major orthopedic or general surgery, and patients experiencing prolonged immobility or hypercoagulable states Pathophysiologically driven by Vir...
- nih.gov
This clinical indication is targeted toward at-risk populations, including acutely ill medical inpatients, individuals undergoing major orthopedic or general surgery, and patients experiencing prolonged immobility or hypercoagulable states
- nih.gov
This clinical indication is targeted toward at-risk populations, including acutely ill medical inpatients, individuals undergoing major orthopedic or general surgery, and patients experiencing prolonged immobility or hypercoagulable states Pathophysiologically driven by Virchow's triad—venous stasis, endothelial injury, and hypercoagulability—uninhibited thrombus generation risks clinical manifestations such as limb pain and edema
- nih.gov
Prophylaxis primarily serves to avert severe sequelae, most critically lethal pulmonary embolism and long-term post-thrombotic syndrome
Personalize your experience
Follow Deep vein thrombosis prevention and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.